View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 24, 2022

Ascletis doses first patient in Phase III glioblastoma treatment trial

The trial will analyse the safety, progression-free survival and overall survival of ASC40 in rGBM patients in China.

Ascletis Pharma has announced the dosing of the first subject in the Phase III clinical trial of ASC40 plus bevacizumab to treat recurrent glioblastoma (rGBM). 

An oral, selective fatty acid synthase (FASN) inhibitor, ASC40 hinders energy supply and interrupts membrane phospholipid composition of tumour cells by hindering de novo lipogenesis (DNL).

FASN is a crucial enzyme that controls DNL.

The multicentre, randomised, placebo-controlled, double-blind trial will assess the safety, progression-free survival (PFS) and overall survival (OS) of ASC40 in rGBM patients in China. 

Nearly 180 subjects will be categorised into a 1:1 ratio to either cohort 1 to receive a once a day oral dose of ASC40 plus bevacizumab or cohort 2 to receive placebo plus bevacizumab. 

Ascletis anticipates randomising and enrolling approximately 80% of these subjects in the trial by the end of December this year.

According to data from the Phase II trial concluded in the US, individuals with rGBM demonstrated to have an objective response rate (ORR) of 65% on treatment with ASC40 plus bevacizumab.

Furthermore, ASC40 plus bevacizumab offered a complete response (CR) and a partial response (PR) of 20% and 45%, respectively.

Ascletis founder, chairman and CEO Dr Jinzi Wu said: “Dosing the first patient in ASC40 Phase III registration study is a significant milestone for our oncology pipeline. 

“We are looking forward to the data from this Phase III study.”

Apart from FASN inhibitors, oncology pipeline of Ascletis includes two oral PD-L1 small molecule inhibitors, ASC61 and ASC63. 

Ascletis has submitted an Investigational New Drug (IND) application in the US for ASC61 to treat advanced solid tumours.

Earlier, the company dosed the first participant in Phase II trial of ASC40 for the treatment of moderate-to-severe acne. 

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy